57352-25-7

Upstream product

• 10345-87-6 3-phenylcyclohex-2-enone 
• 151-50-8 potassium cyanide 
• 100-58-3 phenylmagnesium bromide 
• 5323-87-5 3-Ethoxycyclohex-2-en-1-one 
• 143-33-9 sodium cyanide 

Downstream Products

• 61054-84-0 7-Phenyl-1,4-dioxaspiro<4.5>decan-7-carbonitril 
• 57352-26-8 3-Oxo-1-phenyl-cyclohexanecarboxylic acid methyl ester 
• 75946-08-6 1-Phenyl-6-azabicyclo<3.2.1>octan 
• 61054-65-7 3-Oxo-1-phenyl-cyclohexancarbonsaeureamid 
• 75946-10-0 6-Oxo-4-phenyl-3-isoquinuclidone 
• 75946-09-7 4-Brom-3-oxo-1-phenyl-cyclohexancarbonsaeureamid 
• 75946-05-3 7-Phenyl-1,4-dioxaspiro<4.5>decanecarboxamide 
• 75946-07-5 5-(2-Hydroxyethoxy)-1-phenyl-6-azabicyclo<3.2.1>octan-7-on 
• 75946-06-4 Essigsaeure-2-(7-oxo-1-phenyl-6-azabicyclo<3.2.1>oct-5-yloxy)-ethylester 
• 1429045-46-4 C₂₂H₂₃F₆NO 
• 1429045-47-5 C₂₂H₂₃F₆NO 
• 1429045-48-6 C₂₃H₂₅F₆NO 
• 1429045-49-7 C₂₃H₂₅F₆NO 
• 874375-80-1 3,3-ethylenedioxy-1-phenylcyclohexanecarbaldehyde 

Relevant academic research and scientific papers

Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression

This report describes the synthesis, structure-activity relationships and activity of piperidine, homopiperidine, and azocane derivatives combining NK1 receptor (NK1R) antagonism and serotonin reuptake transporter (SERT) inhibition. Our studies culminated in the discovery of piperidine 2 and homopiperidine 8 as potent dual NK1R antagonists-SERT inhibitors. Compound 2 demonstrated significant activity in the gerbil forced swimming test, suggesting that dual NK1R antagonists-SERT inhibitors may be useful in treating depression disorders.

Homopiperidine derivatives as NK-1 antagonists

The present disclosure relates to chemical compounds and their use in human therapy. In a specific embodiment, compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.

Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists

The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment of the disclosure relates to compounds of Formula (I); or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds are useful for the useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors.

Fused heterocyclic compounds

A compound of formula I wherein m, n, A, B, D, E, G, H, Y, R1, R2, R3, R4, R5, and R8, are described herein.